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Abstract
Background: An important phenomenon observed in glioma metabolism is increased aerobic glycolysis in tumor
cells, which is generally referred to as the Warburg effect. Transforming growth factor (TGF)-beta2, which we
previously showed to be induced by lactic acid, is a key pathophysiological factor in glioblastoma, leading to
increased invasion and severe local immunosuppression after proteolytic cleavage from its latency associated
peptide. In this study we tested the hypothesis, that lactate regulates TGF-beta2 expression and glioma cell migration
via induction of Thrombospondin-1 (THBS-1), a TGF-beta activating protein.
Methods: Lactate levels were reduced by knockdown of LDH-A using specific small interfering RNA (siRNA) and
competitive inhibition of LDH-A by sodium oxamate. Knockdown of THBS-1 was performed using specific siRNA.
Western Blot, qRT-PCR, and ELISA were used to investigate expression levels of LDH-A, LDH-B, TGF-beta2 and
THBS-1. Migration of cells was examined by Spheroid, Scratch and Boyden Chamber assays.
Results: Knockdown of LDH-A with subsequent decrease of lactate concentration leads to reduced levels of THBS-1
and TGF-beta2 in glioma cells. Lactate addition increases THBS-1 protein, leading to increased activation of TGF-
beta2. Inhibition of THBS-1 reduces TGF-beta2 protein and migration of glioma cells. Addition of synthetic THBS-1
can rescue reduced TGF-beta2 protein levels and glioma cell migration in siLDH-A treated cells.
Conclusion: We define a regulatory cascade between lactate, THBS-1 and TGF-beta2, leading to enhanced
migration of glioma cells. Our results demonstrate a specific interaction between tumor metabolism and migration
and provide a better understanding of the mechanisms underlying glioma cell invasion.
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Introduction
More than 60 years ago, Otto Warburg described the
phenomenon of “aerobic glycolysis” [1,2]. In solid tumors,
despite sufficient oxygen, lactate dehydrogenase (LDH)
metabolizes pyruvate to lactate. A subtype of LDH, LDH-A, is
up-regulated in glioma cells [3] which leads to production of the
enzymes LDH IV and V, that mainly metabolize pyruvate to
lactate, whereas higher expression of LDH-B leads to formation
of LDH I, II and III catalysing the oxidation of lactate to
pyruvate. Human in vivo 18fluor-deoxy-glucose positron
emission tomography (FDG-PET) and proton magnetic
resonance spectroscopy (1H-MRS) reveal elevated glucose [4]
and lactate [5] uptake in gliomas, related to their grade. These
observations indicate increased glycolysis. As a consequence,
the end product of glycolysis, lactate, is produced and secreted
in co-transport with protons by monocarboxylate transporters
(MCTs). This leads to accumulation of lactate in the tumor
microenvironment and to acidification [6]. Consecutive
decreases in the extracellular pH [7] lead to several effects
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including increased migration of tumor cells [8,9]. Based on
these results, glioblastoma is a paradigmatic tumor for the
investigation of the role of glycolysis in tumor cell invasion.
TGF-beta2 is a key factor in glioblastoma pathogenesis [10].
Expression of TGF-beta2 correlates with glioma grade [11]. In
tumor tissue TGF-beta2 leads to immune suppression as well
as increased tumor growth, invasion, and metastasis [12,13].
Besides, TGF-beta2 serves as a potent inducer of
angiogenesis [14] and of extracellular matrix-molecules [15].
Lactic acid has been shown to promote glioma migration by
TGF-beta2 dependent regulation of matrix metalloproteinase-2
(MMP-2) [16]. However, the mechanism how lactic acid
influences expression of TGF-beta2 and the role of activators
of TGF-beta, such as THBS-1, has not been investigated in this
context so far.
THBS-1 is an extracellular matrix molecule involved in
glioma migration, invasion, suppression of angiogenesis and
activation of TGF-beta [17,18]. THBS-1 belongs to a group of
structurally related glycoproteins, named THBS-1, THBS-2,
THBS-3, THBS-4 und THBS-5 / cartilage oligomeric matrix
protein [19]. Physiologically, THBS-1 is secreted by platelets;
however, a number of other cells including smooth muscle
cells, astrocytes, endothelial cells and various tumor cells are
also able to produce THBS-1 [20]. The structural complexity of
THBS-1 that consists of an amino-terminal heparin-binding
domain, a procollagen-like domain, 3 type I (properdin-like)
repeats, 3 type II (epidermal growth factor-like) repeats, 7 type
III (calcium-binding) repeats and a carboxy-terminal cell binding
domain explains the various functions of this molecule
predominantly mediated by different cell and extracellular
matrix binding sites [17,21]. Kawataki et al. were able to
provide evidence that THBS-1 and TGF-beta2 correlate with
glioma grade, showing higher expression levels in malignant
high-grade gliomas, than in low-grade gliomas [22]. Further,
THBS-1 increases glioma migration through TGF-beta2
dependent and independent pathways [23]. Activation of TGF-
beta2 is induced by binding of THBS-1 to TGF-beta´s latency
associated peptide, permitting proteolytic cleavage [24,25].
We showed earlier that incubation of glioblastoma cell lines
with lactic acid induces the expression of TGF-beta2 [16].
Furthermore previous experiments indicate that down-
regulation of LDH-A by specific siRNA (siLDH-A), followed by
decreased lactate levels, suppresses TGF-beta2. By means of
microarray analysis (Affymetrix U133; Affymetrix, Santa Clara,
CA, USA; unpublished results), we could also demonstrate that
decreased lactate down-regulates THBS-1 mRNA, a pivotal
TGF-beta activating protein. We therefore hypothesized that
LDH-A-mediated changes in local lactate levels modulate the
activation of TGF-beta2, which is mediated, at least in part, via
THBS-1.
Materials and Methods
Culture of glioma cell lines
Glioma cell lines and primary cultures were used for in vitro
experiments. The human glioblastoma cell lines U87MG and
A172 were obtained from American Type Culture Collection
(Manassas, VA, USA). The gliomas named as “HTZ” were
primary tumor cell cultures derived from surgical specimens of
human glioblastomas, as described [15]. Tumor cells were
maintained as monolayer cultures in Dulbecco’s Modified Eagle
Medium (DMEM; PAA, Pasching, Austria), supplemented with
5% fetal calf serum (FCS; PAA, Pasching, Austria) at 37°C, 5%
CO2, 95% humidity in a standard tissue culture incubator.
Core results were verified in cultures of brain tumor initiating
cells (BTIC, supplementary data) [26,27], that were established
from resections of untreated human malignant gliomas.
Progenitor features of BTIC lines were verified by
multiparametric flow cytometry [27] using established markers
of BTIC (CD133, CD15, CD44, A2B5), markers of progenitor
cells (Nestin, Sox2, GFAP), by clonogenicity assays and partly
by tumor take assays in the nude mouse model. RAV20 cells
(anaplastic astrocytoma, IDH1mut, MGMT promoter methylation
not performed, CD133+, CD15+, CD44 n.d., A2B2-, Nestinhigh,
Sox2moderate, GFAPlow, proneural phenotype, clonogenicity +,
tumor take +) were derived from a 30 year-old patient, RAV21
cells (primary glioblastoma, IDH1wt, MGMT promoter
methylation 100%, CD133-, CD15-, CD44+, A2B2+, Nestinlow,
Sox2low, GFAPmoderate, mesenchymal phenotype, clonogenicity
+, tumor take +) were extracted from a 46-year old patient.
BTIC cell lines with moderate to high proliferation rates,
expression of THBS-1 and TGF-beta2, and a functional TGF-
beta signaling pathway [28] verified by Smad2 phosphorylation
after TGF-beta treatment, were used for this project. Use of
human material has been approved by the institutional review
board of the University of Regensburg, Germany (No°
11-103-0182). All participants provided written informed
consent to participate in this study. Human dermal fibroblasts
were provided by Dr. Tim Maisch, Department of Dermatology,
University Hospital Regensburg.
Treatment of glioma cell lines with lactate, lactic acid
and sodium oxamate
Glioma cell lines and controls were treated with sodium
lactate (Sigma, Germany), lactic acid (Sigma, Germany), HCl
as pH control (Merck, Germany) and sodium oxamate (Fluka,
Germany). Cells were seeded in 6-well plates, maintained in
serum-free conditions over night and incubated with different
concentrations (0, 5, 10, 20 mM) of lactate for 24 hours. After 2
hours and before harvest, pH was controlled and if necessary
adjusted to pH 7.1. Starved cells were treated by different
concentrations of sodium oxamate (Fluka, Germany) for 24 h.
Cells and supernatants were harvested to prepare total RNA or
protein as described below. Cell lysates and supernatants of
untreated cells were used as controls in all assays.
Magnetic resonance spectroscopy
Metabolic analysis of lactate and glucose before and after
treatment was performed by nuclear magnetic resonance
spectroscopy (1H-NMR, Bruker Avance 600 MHz spectrometer,
Bruker, Germany) as published [29]. Briefly, 600 µl of cell
culture supernatants containing 50 µM dimethyl-
silapentanesulfonate (DSS, internal standard for quantification)
and 10% D2O were filled into standard 500 µl NMR tubes
(Norell Inc., Landisville, NJ). One-dimensional NOESY spectra
(Bruker pulse sequence noesygppr1d) were acquired with a
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repetition time of 10 seconds, a mixing time of 10 ms, and a
weak presaturation pulse of 8.2 seconds to suppress the water
signal. Sixteen scans with 32,768 datapoints and a sweepwidth
of 8993 Hz were accumulated followed by an exponential line
broadening of 0.3 Hz. The spectra were corrected for baseline
and phase artifacts manually, and the frequency of the methyl
peak of DSS was set to 0.00 ppm. Quantities of lactate and
glucose were obtained by fitting model spectra of known
metabolites (biorefcode database, Bruker, Germany) to the
data by means of a standard Matlab (The MathWorks, Natick,
MA, USA) optimization routine.
Measurement of LDH V activity and extracellular lactate
concentration
2x105 glioma cells or fibroblasts were seeded in 6-Well
plates and treated with siLDH-A or sodium oxamate for 24
hours. Then, cells were counted and 5x103 of these cells were
transferred into 96-Well plates and lysed to measure LDH V
activity using the cytotox assay (Promega, Germany) according
to the manufacturer’s instructions. Lactate levels in cell culture
supernatants were measured with a COBAS analyzer (Roche,
Germany), measuring 2x103 of the differentially treated cells.
Transient transfection of glioma cell lines for LDH-A,
LDH-B and THBS-1 knockdown
Transient transfection of glioma cell lines and BTIC using
Lipofectamin 2000 (Invitrogen GmbH, Darmstadt, Germany)
was performed with 0.1-0.2 µM siRNA against LDH-A (siLDH-
A), LDH-B (siLDH B) and THBS-1 (siTHBS-1) to evaluate
mRNA level changes after 12, 24, 48, and 72 hours and to
generate about 90% knockdowns of the respective proteins.
pH measurement
For pH measurement, a pH-electrode (HANNA Instruments,
Kehl am Rhein, Germany) was calibrated at 37°C, and the pH
of the cell supernatant was measured directly in the incubator
immediately after opening of the incubator and cell culture
flask.
THBS-1 and TGF-beta2 stimulation assays
To investigate the effect of exogenous THBS-1 and TGF-
beta2 on the function of glioma cells we performed in vitro
stimulation assays. We seeded 2x105 glioma cells in 6-well
plates. After 24 hours, triplicates of subconfluent cell layers
were treated with 20 ng/ml rhTGF-beta2 protein (R&D Systems
GmbH, Germany) or recombinant human THBS-1 protein (R&D
Systems GmbH, Germany, Asn 19 - Pro 1170; Accesion
#P0799) [30] as indicated in the text and incubated for 72
hours. Cells and supernatants were harvested to prepare total
RNA or protein as described below or to investigate the cells in
Scratch Migration Assays as indicated below.
RNA isolation
For RNA isolation, cells were incubated in 6-well plates (2
x105 cells per 2 ml). Total RNA was isolated using the RNeasy
Mini Kit (Qiagen, Germany) and reverse transcribed using M-
MLV reverse transcriptase (Promega, Germany) following the
manufacturer’s instructions.
Polymerase Chain Reaction (PCR) and Quantitative
Real Time PCR (qRT-PCR)
Primers to detect transcripts of interest were: LDH-A
(forward: 5'-GGT TGG TGC TGT TGG CAT GG-3’, reverse: 5'-
TGC CCC AGC CGT GAT AAT GA-3‘, Genbank Accession No:
NM_001135239.1), THBS-1 (forward: 5’-CAG AAG GAC TCT
GAC GGC G-3’, reverse: 5’-GAA TCA TCT GGA ATC GGC
GG-3’, Genbank Accession No: NM_003246.2), TGF-beta2
(forward: 5' CAC CAT AAA GAC AGG AAC CTG -3'; reverse: 5
´- GGA GGT GCC ATC AAT ACC TGC -3´, Genbank
Accession No: NM_003238), and RPLPO (large ribosomal
protein) (forward: 5’-CTG TCT GCA GAT TGG CTA CCC-3’,
reverse: 5’-GAT GGA TCA GCC AAG AAG GC-3’, Genbank
Accession No: NM_001002.3) as a positive control in all
assays. Annealing temperatures were optimized for each
primer pair. PCR products were analyzed on a 1% agarose gel
and visualized with ethidium bromide staining.
Quantification of mRNA expression was performed by real-
time PCR (Mx3000P Quantitative PCR [qPCR] System,
Stratagene, Germany) based on SYBR-Green I fluorescence
(QuantiFast SYBR Green PCR Kit Qiagen, Germany). Briefly,
five serial twofold dilutions of cDNA were amplified in triplicate
to construct standard curves for both the target gene and the
endogenous reference (18s or RPLPO, ribosomal protein,
large, P0). For each reaction, melting curves and agarose gel
electrophoresis of PCR products were used to verify the
identity of the amplification products. The target gene amount
was divided by the endogenous reference (18s or RPLPO)
amount to obtain a normalized target value. Each of the
experimental normalized values was divided by the normalized
control (untreated) sample value to generate the relative
expression levels in fold changes.
Protein isolation
To confirm knockdown effects of LDH-A and THBS-1 on the
protein level, whole-cell lysates were prepared with RIPA
buffer, and the samples (10-30 µg) were subjected to Western
blotting on a denaturing 10% SDS-PAGE.
TGF-beta2 ELISA
For quantitative determination of activated human TGF-beta2
concentrations in cell culture supernatants, the quantitative
sandwich enzyme linked immunoassay technique was used
with a commercially available human TGF-beta2 specific
immunoassay kit (R&D Systems, Minneapolis, MN). The
minimum detectable dose of TGF-beta2 was less than 7.0
pg/ml. The assay was performed in triplicate according to the
manufacturer’s instructions.
Western Blot
For detection of all other proteins, SDS-PAGE and Western
Blot on a nitrocellulose membrane (Bio-Rad Laboratories,
Munich, Germany) was performed. Monoclonal antibodies
specific for LDH-A, THBS-1, TGF-beta2 (Santa Cruz
Lactate-Modulated Induction of THBS1
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Biotechnology, Germany), βActin (Sigma-Aldrich, Germany),
pSmad2 (Calbiochem, Germany) and LDH-B (Abnova,
Germany) were used. Immunocomplexes were visualized using
horseradish peroxidase-conjugated antibodies (BD Bioscience,
Heidelberg, Germany) followed by enhanced
chemoluminescence (ECL) with Immobilon Western HRP
Substrate (Millipore GmbH, Schwalbach, Germany) and
detection on Hyperfilm ECL 1 (Amersham, Munich, Germany).
Proliferation assays
Proliferation of glioma cells was determined by counting
viable cells using a Neubauer chamber. Non-viable cells were
identified by trypan blue. Every experiment was performed in
triplicate and repeated twice.
Scratch Migration Assay
In order to determine glioma cell migration with the Scratch
migration assay, 2 x 105 glioma cells were seeded in each well
of a 6-well plate. An artificial gap, a so called “scratch” was
created in the confluent cell monolayer using a pipette tip.
Images were captured at the beginning and regular intervals
(24, 48, 72 and 96 hours) during cell migration into the scratch,
and the area of the “scratch” was measured in µm2 and
compared between images in order to determine the rate of cell
migration as ∆µm2. Assays were performed in triplicate,
repeated twice and evaluated by a blinded investigator.
Spheroid Migration Assay
Tumor spheroids were initiated by seeding 3-8 x 103 cells in
agar-coated wells. Mature spheroids with a mean diameter of
200-250 µm were explanted to uncoated 96 well plates.
Spheroids were allowed to migrate for 1-5 days using the
earliest time point where migration was visible to prevent a
dilution of the effect by enhanced proliferation of cells. The
diameter of the area covered by cells migrating away from a
spheroid was photographed and the diameter was measured
manually by a blinded investigator using the greatest diameter.
Bovine serum albumin (BSA) was used as a control protein.
Assays were performed in triplicate and repeated twice.
Boyden Chamber Migration Assay
A suspension of 200,000 tumor cells per ml (total volume:
200 µl) was pipetted in the upper chamber of the Boyden
device (Becton Dickinson, USA). The lower chamber was
loaded with 210 µl of a chemo-attractant consisting of cell
culture medium that had been harvested after a 24-h
incubation of fibroblasts grown in DMEM. The chambers are
divided by an uncoated membrane with pores of 8 µm
diameter. After 4 h of incubation, the number of cells that had
migrated to the lower side of the membrane was counted after
staining with hematoxilin and eosin. Five visual fields were
counted by a blinded investigator on each filter of a triplet and
were evaluated calculating means of migrated cells and
standard deviation.
Statistics
The Student`s t-test (paired/equal variance) was used to
compare the results (mean values and SDs) of control vs.
treated cell samples. The level of significance was set at
*P<0.05, **P<0.01, and ***P<0.001.
Results
Expression of LDH-A and secretion of lactate in glioma
cell lines
To verify a relevant activity of LDH-A in glioma cell lines, we
evaluated baseline LDH-A expression levels and lactate
secretion in glioma cell lines HTZ-349 and U87. Glioma cell
lines expressed considerable levels of LDH-A at the mRNA
(Figure 1A) level. Protein expression was investigated in
several glioma cell lines (HTZ-349, U87, A172), a malignant
melanoma cell line (MelIm) and a prostatic cancer cell line
(PC3), all expressing LDH-A at much higher levels as human
fibroblasts (Figure 1B). The expression of LDH-A and LDH-B
did not differ under starving conditions and conditions using 5%
of FCS (not shown). Levels of lactate, secreted to the
supernatants of these cell lines (Figure 1C), correlate to LDH-A
expression, therefore suggesting also relevant activity of LDH-
A. Lactate concentration was measured at a cell number of
2*105 cells/well to avoid confounding by experimental
variations. Fibroblasts and brain from hippocampal resections
in epileptic patients were used as control and showed
considerable lower expression of LDH-A (Figure 1A) and
lactate secretion (Figure 1C).
Regulation of glioma cell migration by lactate
Migration is a key feature of glioma malignancy. To evaluate
if lactate is able to modulate glioma cell migration, we
performed Boyden Chamber assays with U87 and HTZ-349
glioma cells. Treatment of U87 or HTZ-349 glioma cells with 20
mM sodium lactate corresponds to levels measured in brain
tumor specimen9 and led to a highly significant increase in
glioma cell migration 24 hours after treatment (Figure 2A, B).
Hydrochloric acid alone failed to significantly enhance HTZ-349
glioma cell migration (Figure 2A), whereas U87 glioma cells
also showed moderately increased migratory capacity after
acidification by hydrochloric acid (Figure 2B).
Next, we tested how glioma cell migration is regulated after
reduction of lactate levels. We therefore treated HTZ-349 and
U87 glioma cells with sodium oxamate, a competitive inhibitor
of LDH. As a structural analogue of pyruvate, sodium oxamate
inhibits LDH V catalyzed conversion of pyruvate into lactate.
Treatment with 25 mM sodium oxamate and above led to a
significant 30-40% inhibition of LDH enzyme activity in
HTZ-349 and U87 (Figure 3A). Increasing the dose of sodium
oxamate to 50 mM enhanced LDH inhibition to 51% in
HTZ-349 glioma cells and 57% in U87. Correspondingly,
lactate levels decreased in a dose- and time-dependent way
after treatment with sodium oxamate (Figure 3B, C). In
spheroid migration assays treatment with sodium oxamate led
to a dose-dependent highly significant decrease of HTZ-349
and U87 glioma cell migration 24 hours after treatment (Figure
3D, E) as well as in Boyden chamber assays (Figure 3F). To
Lactate-Modulated Induction of THBS1
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avoid confounding effects by impaired cell proliferation and
apoptosis, pre-tests were performed to confirm that reduced
cellular proliferation by oxamate is starting 24 hours after
treatment in both cell lines, therefore supporting a true effect on
migration in that assays that are consistently harvested before
24 hours (Figure S1A, S1B).
Influence of lactate on the expression of TGF-beta2
As TGF-beta is a known inductor of migration in glioma, we
next hypothesized that lactate might induce glioma cell
migration by regulation of TGF-beta2. To test this hypothesis,
we regulated lactate production by transfecting cells with
siLDH-A and monitored for changes of TGF-beta2 levels.
Treatment of glioma cells with 0.1 µM siLDH-A specifically
suppressed mRNA of LDH-A in HTZ-349 glioma cells to 2% of
the initial levels (Figure 4A), leading to decreased levels of
lactate and a parallel moderate increase of glucose (Figure
S2A). Regulation of LDH-A RNA was followed by regulation of
LDH-A but not LDH-B protein (Figure 4B). LDH-A, but not LDH-
B knockdown also led to a decrease in TGF-beta2 mRNA
(Figure 4A) and TGF-beta2 protein in TGF-beta2 Western blot
(Figure 4B) and ELISA (Figure 4C), with a maximum regulation
72 hours after transfection (Figure 4D). Experiments in U87
yielded consensual results (not shown). These results were
confirmed in RAV20 and RAV21 brain tumor initiating cells with
similar results (Figure S3A).
Correspondingly, lactic acid and sodium lactate, but not
hydrochloric acid significantly increased TGF-beta2 mRNA in
HTZ-349 glioma cells (Figure 4E). These results were
confirmed in RAV20 brain tumor initiating cells with consensual
results (Figure S3B). Furthermore, TGF-beta2 protein
increased modestly after treatment with sodium lactate and
significantly after treatment with lactic acid and even more
pronounced after treatment with hydrochloric acid after 24
Figure 1.  Glioma cell lines express LDH-A and secrete lactate.  Glioma cell lines HTZ-349 and U87 were cultured under
comparable conditions. Using qRT-PCR, mRNA levels of LDH-A were determined using specific primers for LDH-A (A). Additionally,
total protein was isolated and LDH-A and LDH-B protein expression was determined in Western Blot analysis (B). Glioma cell lines
have increased mRNA levels of LDH-A in comparison to fibroblasts and human brain RNA (A, p < 0.05*) and show increased
protein expression, as do a melanoma cell line (MelIm) and a prostatic cancer cell line (PC3) (B). To examine lactate expression cell
culture supernatants (2*105 cells/well) were collected and lactate levels were measured (C). Glioma cell lines secrete higher levels
of lactate if compared to fibroblasts (U87, p < 0.01**; HTZ-349 p < 0.05*).
doi: 10.1371/journal.pone.0078935.g001
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hours (Figure 4F), suggesting a direct protein processing effect
of acid in this context. This effect was reproduced in cells
cultured with 5% FCS (Figure S2B) to exclude a starving effect.
All assays were repeated in U87 with similar results (not
shown).
Regulation of THBS-1 expression by lactate
As THBS-1 is a potential activator of TGF-beta2 expression
in glioma lines, we next investigated the influence of LDH-A
knockdown and lactate on THBS-1 expression. qRT-PCR and
Western Blot analysis were performed to examine THBS-1
after siLDH-A treatment. LDH-A knockdown by siLDH-A
reduced THBS-1 significantly at the mRNA (Figure 5A) and
protein level (Figure 5B, C) in HTZ-349 and U87 glioma cells.
Subsequently TGF-beta2 and pSmad2, a pivotal signaling
molecule of the TGF-beta pathway, but not unphosphorylated
Smad2 (not shown), were down-regulated (Figure 5B). Results
were confirmed in RAV21 brain tumor initiating cells with
consensual results (Figure S3C).
In accordance to these results treatment with 20 mM sodium
lactate or 20 mM lactic acid significantly induced THBS-1 in
U87 and HTZ-349 glioma cells at the mRNA level. Acidification
with hydrochloric acid alone had no significant effect (Figure
5D, E). At the protein level, treatment with lactic acid and
lactate, but not hydrochloric acid also induced THBS-1,
indicating that the lactate anion and not acidification regulates
THBS-1 expression (Figure 5F). Similar results were obtained
in RAV20 brain tumor initiating cells, however, HCl yielded a
significant increase of THBS-1 in these cells (Figure S3D).
Treatment of siLDH-A transfected HTZ-349 glioma cells with
sodium lactate and lactic acid almost fully rescued impaired
THBS-1 expression confirming that lactate levels induce
THBS-1 expression independent of LDH-A (Figure 5D).
Interaction of THBS-1 and TGF-beta2
After knockdown of LDH-A by specific siLDH-A, THBS-1 was
down-regulated at the protein level (Figure 5B). In addition,
TGF-beta2 as a known THBS-1 activated protein and
phosphorylation of the TGF-beta signaling pathway molecule
Figure 2.  Glioma cell migration is enhanced after treatment with sodium lactate.  HTZ-349 (A) and U87 (B) glioma cells were
treated with 20 mM sodium lactate (pH 7.4) and HCl (pH 7.1) was used as control. 24 hours after treatment cell migration was
analyzed using Boyden Chamber assays. The Y-axis indicates number of migrated cells. Treatment with lactate leads to a highly
significant increase in glioma cell migration (U87 and HTZ-349, p < 0.001***).
doi: 10.1371/journal.pone.0078935.g002
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Figure 3.  Glioma cell migration is reduced after competitive inhibition of LDH-A.  Sodium oxamate was used for competitive
inhibition of LDH. LDH activity was determined using the cytotox assay (Promega, Germany). Treatment with increasing doses of
sodium oxamate (5 mM-75 mM) significantly reduces LDH activity 24 hours after treatment (HTZ, 349 p < 0.01** for 25mM, 50 mM
and 75 mM sodium oxamate; U87, p < 0.001*** for 25mM, 50 mM and 75 mM sodium oxamate, fibroblasts, p < 0.01** for 10 mM
and p < 0.001*** for 25mM, 50 mM and 75 mM sodium oxamate). HTZ 349 and U87 showed significantly higher LDH activity
compared to fibroblasts (HTZ-349 p < 0.01##, U87 p < 0.001###) (A). Lactate levels were measured in cell culture supernatants 24
hours after treatment with increasing doses of sodium oxamate (10 mM-75 mM). Treatment with sodium oxamate leads to a dose-
(B) and time-dependent reduction (C) of extracellular lactate levels. Treatment with 25 mM and 50 mM sodium oxamate significantly
reduces HTZ-349 (D) and U87 (E) glioma cell migration starting 24 hours after treatment (HTZ, 349 p < 0.001*** at 24 h and 32 h for
25 and 50 mM sodium oxamate; U87, p < 0.05* at 24 h, p< 0.01** at 32 h for 50 mM sodium oxamate). (F) Boyden chamber assay
showing similar effects as in (D) and (E) (U87, p< 0.001***; HTZ-349, p < 0.001***). The Y-axis indicates the number of migrated
cells. Results were normalized to control.
doi: 10.1371/journal.pone.0078935.g003
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Smad2 were reduced (Figure 5B), suggesting a possible
cascade effect initiated by lactate-induced regulation of
THBS-1. To further elucidate the interaction between THBS-1
and TGF-beta2, we designed a specific siRNA against
THBS-1, which was able to inhibit THBS-1 at the mRNA
(Figure 6A) and protein level (Figure 6B) for up to 96 hours,
with a maximum reduction of 95% 72 hours after transfection.
Accordingly, THBS-1 knockdown led to a statistically significant
Figure 4.  Lactate regulates TGF-beta2 protein.  Specific siRNA against LDH-A was used to reduce extracellular lactate levels
and to investigate consecutive changes in TGF-beta2 expression. siLDH-A reduces LDH-A (p < 0.01**) and TGF-beta2 (p< 0.05*)
mRNA expression significantly 72 hours after treatment (A). In TGF-beta2 Western Blot (B) and ELISAs (C, D) siLDH-A reduces
TGF-beta2 protein expression with a maximum reduction 72 hours after treatment (p< 0.001***). Results were normalized to control.
Treatment with 20 mM lactic acid (pH 7.1) as well as 20 mM sodium lactate (pH 7.4) increases TGF-beta2 mRNA (E). Expression of
TGF-beta2 protein 24 hours after treatment is significantly increased by lactic acid, lactate and HCl (F, lactic acid p < 0.05*; sodium
lactate p < 0.01**, HCl p < 0.05*).
doi: 10.1371/journal.pone.0078935.g004
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75% reduction of TGF-beta2 protein 72 hours after treatment
(Figure 6C) that begins at 48 hours and holds for at least 96
hours. Notably, decreased levels of TGF-beta2 protein after
LDH-A knockdown at the time of maximum regulation could be
Figure 5.  Regulation of THBS-1 expression by lactate.  mRNA levels of THBS-1 were examined in qRT-PCR using specific
primers for THBS-1. Treatment of glioma cells with 0.1 µM siLDH-A significantly suppresses THBS-1 at the mRNA level in HTZ-349
and U87 glioma cells (A, HTZ-349 p < 0.001***; U87 p < 0.05*). Western blot analysis was used to determine LDH-A and THBS-1
protein expression after treatment with siLDH-A. β-Actin was used as a loading control. Suppression of LDH-A also leads to a
reduction of THBS-1 protein in HTZ-349 (B) and U87 (C) glioma cells. Further, TGF-beta2 expression and pSmad2 are markedly
suppressed after siLDH-A treatment in HTZ-349 glioma cells (B). Treatment with 20 mM sodium lactate (pH 7.4) or 20 mM lactic
acid (pH 7.1) significantly induces THBS-1 in HTZ-349 (D) and U87 (E) glioma cells at the mRNA level 24 hours after treatment
(HTZ-349 p < 0.05*; U87 for lactic acid p < 0.01**, for sodium lactate p < 0.001***). Treatment of siLDH-A transfected HTZ-349
glioma cells with sodium lactate and lactic acid can fully rescue impaired THBS-1 expression (HTZ-349 p < 0.05# for sodium lactate
and lactic acid after siLDH-A transfection) (D). Western Blot analysis confirmed induction of THBS-1 protein in U87 glioma cells after
treatment with lactic acid and sodium lactate (F).
doi: 10.1371/journal.pone.0078935.g005
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significantly rescued by addition of increasing doses of
synthetic THBS-1 protein (Figure 6D), indicating a relevant
activating effect of THBS-1. In addition, treatment of siTHBS-1
transfected cells with lactic acid and sodium lactate failed to
relevantly activate TGF-beta2, substantiating the role of
THBS-1 as a major link between lactate and TGF-beta2 (Figure
6E). All assays were reproduced in U87 with similar results (not
shown).
Figure 6.  Knockdown of THBS-1 down-regulates TGF-beta2 at the protein level.  0.1 µM of siTHBS-1 significantly inhibit
THBS-1 at the mRNA level as assessed in qRT-PCR (A, p< 0.05*). Western Blot analysis showed markedly reduced THBS-1
protein levels over 96 hours after treatment with siTHBS-1, with a maximum reduction 72 hours after treatment (B). In TGF-beta2
ELISAs siTHBS-1 causes significant down-regulation of TGF-beta2 protein in HTZ-349 glioma cells with a maximum reduction at 72
hours (C, p < 0.05*). Decreased levels of TGF-beta2 protein after LDH-A knockdown (D, mock/siLDH-A p < 0.05*) can be rescued
by addition of increasing doses of synthetic THBS-1 protein (siLDH-A/siLDH-A+6 µg/ml THBS-1, p < 0.05#). Lactic acid and sodium
lactate fail to significantly induce TGF-beta2 expression after transfection with siTHBS-1 (E, significance is indicated as compared to
mock treated cells with standard medium, p < 0.05*).
doi: 10.1371/journal.pone.0078935.g006
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Modulation of glioma cell migration by TGF-beta2 and
THBS-1
To investigate the functional relevance of THBS-1 and TGF-
beta2 on glioma cell migration we performed in vitro migration
assays after differential treatment of glioma cells. First, we
examined the migratory capacity of siLDH-A-transfected
HTZ-349 and U87 glioma cells in Boyden (Figure 7A) and
Scratch Migration Assays (Figure 7B). Both cell lines showed
significantly decreased migration after knockdown of LDH-A
(and therefore decreased levels of lactate) in comparison to
controls. Proliferation was not significantly changed after
siLDH-A treatment during the time periods used for migration
assays (Figure S1C, S1D). To verify the initiating capacity of
THBS-1, we examined HTZ-349 and U87 glioma cell migration
after knockdown of THBS-1 (Figure 7C). Again, both cell lines
exhibited significantly reduced migration after siTHBS-1
treatment in Scratch Migration Assays. Proliferation was not
markedly impaired after siTHBS-1 treatment (Figure S1E,
S1F). Finally, we investigated how addition of synthetic
THBS-1 and recombinant TGF-beta2 mediates glioma cell
migration. Addition of 6 µg/ml THBS-1 completely rescued
impaired migration after LDH-A knockdown (Figure 7D). Similar
results were obtained in U87 (not shown). Accordingly, addition
of 20 ng/ml TGF-beta2 also fully restored reduced glioma cell
migration after LDH-A knockdown in HTZ-349 (Figure 7E) and
U87 (Figure 7F) glioma cells, indicating a cascade starting from
lactate that is relevant for the migratory capacity of glioma
cells.
Discussion
Glioma cell migration is a characteristic feature of glioma
malignancy. It depends on several mechanisms. One of the
possible mechanisms, promotion of glioma cell migration by
lactic acid, has been described earlier [16]. However, other
underlying mechanisms are still poorly understood. In this
work, we show for the first time that in addition to TGF-beta
itself, the TGF-beta activating protein THBS-1 is induced by
lactic acid and sodium lactate leading to increased levels of
TGF-beta2 and enhanced glioma cell migration in vitro.
Regulation and activation of TGF-beta underlie complex
mechanisms. TGF-beta is synthesized as pro-TGF-beta
consisting of the mature 24-kDa TGF-beta dimer and the
latency-associated protein (pro-region, LAP). In order to
resolve the non-covalent binding between TGF-beta and LAP
and to activate TGF-beta, activating molecules such as
plasmin, thrombospondin or integrins are needed. Also reactive
oxygen species and acidification has been shown to dissolve
the non-covalent binding between TGF-beta and LAP [31].
Seen in this context, our finding that addition of hydrochloric
acid leads to increased protein, but not mRNA expression of
TGF-beta2 is plausible. Also increased migratory capacity after
acidification with hydrochloric acid is in line with increased
activation of TGF-beta2, a known pro-migratory molecule
[12,13]. TGF-beta activating effects of lactic acid can also be
explained by intracellular acidification, since the dissociation
constant (pKa) for lactic acid is 3.87 (298,15 K) and lactic acid
will therefore rapidly dissociate into lactate and protons under
experimental conditions.
However, for the first time, we also demonstrated an
activating effect of sodium lactate on TGF-beta2 mRNA and
protein as well as on glioma migration. To explain this finding
we examined the TGF-beta activating molecule THBS-1, which
we found to be decreased after siLDH-A treatment.
Interestingly, we could find an increase of THBS-1 mRNA and
protein expression after treatment with sodium lactate and
lactic acid, but not after acidification with hydrochloric acid,
therefore providing a possible explanation of the observed
effects of sodium lactate on TGF-beta2 via its activator protein.
It has been shown earlier that lactate modulates the binding
capacity of AP1 on its consensus sequence by changing the
redox state of the cell. The mentioned redox state change
modulates the expression of target genes of AP1, for example
ETS1 and THBS-1 [32,33]. ETS1 is known to induce
transcription together with AP1. AP1 itself binds to the
promoter of THBS-1 [34], and binding motifs for ETS1 suggest
a functional role of ETS1 at the THBS-1 promoter (affinity
prediction of more than 0.95 by Genomatix search). We
therefore hypothesize that induction of THBS-1 by lactate is
mediated by altered THBS-1 transcription, a mechanism that
that is currently further explored.
Induction of THBS-1 with consecutively increased activation
of TGF-beta2 is therefore one possible mechanism of
enhanced TGF-beta2 protein expression at increased levels of
sodium lactate. To explain the observed effects on TGF-beta2
mRNA level known autocrine effects of TGF-beta have to be
considered. TGF-beta2 secreting cells mostly also posses
TGF-beta receptors and therefore increased levels of active
extracellular TGF-beta2 enhance transcription of pro-TGF-beta
[35,36]. In addition, the above mentioned link between lactate
and AP-1 might also explain effects on TGF-beta mRNA, since
AP-1 also binds to the promoter of TGF-beta [37].
Since a fundamental hypothesis of this work was that
increased levels of THBS-1 lead to increased activation of
TGF-beta2, a mechanism that has been evaluated mostly for
TGF-beta1, we had to confirm activation of TGF-beta2 by
THBS-1 in our cellular model. We were able to show that
knockdown of THBS-1 significantly reduces TGF-beta2 on the
protein level. On the other hand, addition of synthetic THBS-1
increases TGF-beta2 protein. Activation of TGF-beta1 by
THBS-1 is currently understood as a two-step mechanism.
First, the WSXW sequence of THBS-1 allows orientation of
latent TGF-beta, so that the KRFK sequence of THBS-1 is
associated to the corresponding LSKL sequence of the latency
associated peptide, allowing proteolytic cleavage from mature
TGF-beta [24,38,39]. Recent publications indicate that this
mechanism could also apply for TGF-beta2. Zhang et al.
observed that activation of TGF-beta2 in endothelial cells by
hypoxia is dependent on THBS-1 [40]. Additionally, Ribeiro et
al. were able to show that the LSKL sequence of pro-TGF-
beta2 is conserved in all TGF-beta isoforms and that THBS-1
activates TGF-beta2 in Chinese hamster ovarian cells [25]. We
therefore postulate that lactate mediated induction of THBS-1
leads to increased proteolytic cleavage of TGF-beta2, leading
to enhanced expression of TGF-beta2.
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One of the functional experimental readouts of invasion is
migration of glioblastoma cells in vitro. Scratch, Boyden or
spheroid migration assays are reliable methods providing
quantitative results. According to our results, a knockdown of
LDH-A by siRNA with consecutive decreases in lactate levels
leads to an approximately 40% decrease in migration
compared to glioma cells treated with a control siRNA. This
effect can be completely rescued by addition of synthetic
THBS-1 and recombinant human TGF-beta2. TGF-beta2 is a
known activator of glioma cell migration and invasion [12,13].
THBS-1 has also shown to be an activator of glioma cell
migration through TGF-beta2 dependent and independent
Figure 7.  Glioma cell migration is mediated by THBS-1 and TGF-beta2.  Boyden Chamber assays of HTZ-349 and U87 glioma
cells 24 hours after treatment with 0.1 µM siLDH-A show a significant inhibition of migration (A, U87 p < 0.001***; HTZ-349 p <
0.01**). The Y-axis indicates the number of migrated cells. Scratch Migration assays verified these results (B-F). Here, the Y-axis
indicates the area of an artificial gap in the confluent cell monolayer. Inhibition of LDH-A by siRNA yields similar results (B) as in the
Boyden chamber assay. THBS-1 knockdown also diminishes HTZ-349 and U87 migration (C, HTZ-349 p < 0.01**; U87 p <
0.001***). Addition of 6 µg/ml recombinant THBS-1 (D) and 20 ng/ml TGF-beta2 (E, F) can fully rescue impaired migration after
LDH-A knockdown (HTZ-349, p < 0.001*** for decrease of migration after siLDH-A, p < 0.05*,# for induction of migration after
treatment with TGF-beta2; U87, p < 0.01** for decrease of migration after siLDH-A, p < 0.05* for induction of migration after
treatment with TGF-beta2 in mock- and p < 0.001### for induction of migration in siLDHA-transfected TGF-beta2 treated cells).
doi: 10.1371/journal.pone.0078935.g007
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ways. THBS-1 has proven to reduce degradation of uPA by
preventing association of uPA, uPAR and PAI-1, resulting in
increased migration of tumor cells [41,42]. Also, activation of
MMP-2 by THBS-1 in smooth muscle cells is currently under
discussion [43]. We therefore conclude that lactate, by
induction of THBS-1, modulates migration of glioma cells in
vitro through TGF-beta2 dependent and independent ways.
It is important to state, that the observed effects of lactate on
THBS-1 and TGF-beta2 are obtained in a highly artificial
cellular model, using established glioma cell lines. In order to
verify results in a model closer to the in vivo conditions, we
repeated our core results in brain tumor initiating cells.
Besides, control for confounding effects such as altered
proliferation, apoptosis or energy supply after regulation of
lactate has to be discussed, although we did not observe
significant changes in cellular proliferation and ATP production
after siLDH-A transfection in the time periods used for
migration assays (not shown). Also, the level of lactate
transporters, such as MCT-1 and MCT-4, could be affected by
lactate supplementation to cell culture and should be examined
in more detail in further studies [44]. Additionally, the observed
effects of lactate on TGF-beta2 are moderate, however, it is
important to state that the effects of TGF-beta are context- and
concentration-dependent, meaning that the demonstrated level
of regulation can well induce meaningful functional effects [45].
We did not examine TGF-beta1 in detail, since TGF-beta2 is
known to be the more relevant cytokine in glioma biology [46].
Summarized, our results suggest additive effects of lactate
and lactic acid on TGF-beta2 and glioma migration: a
processing effect of protonated lactate on TGF-beta2 protein
via acidification and a cascade effect where lactate induces
TGF-beta2 activation via induction of THBS-1. Processing of
TGF-beta by THBS-1 has been described earlier [24].
However, an effect of aerobic glycolysis on THBS-1 / TGF-
beta2 has not been shown yet. TGF-beta2 is one of the
prominent modulators of glioblastoma pathogenesis. A link to
glycolysis therefore provides another important mechanism
broadening the pathophysiological potential of this pivotal
protein.
Supporting Information
Figure S1.  Control for contributory effects. Proliferation of
HTZ-349 and U87 glioma cells was assessed after treatment
with sodium oxamate, siLDH-A and siTHBS-1. Trypan Blue
was used to control for cell viability. Treatment with sodium
oxamate (A, B) and LDH-A (C, D) significantly (p < 0.05* or p <
0.01**) reduces cell proliferation starting 24 hours after
treatment in both cell lines. Treatment with siTHBS-1 did not
show a significant effect on glioma cell proliferation (E, F).
(TIFF)
Figure S2.  Control for contributory effects. 24 hours after
transfection of HTZ-349 with siLDH-A, lactate levels in the cell
culture supernatant decrease significantly (A; p = 0.05*),
accompanied by an as well significant increase of extracellular
glucose (p = 0.05*) as assessed by mass spectrometry
according to [16]. In addition, we investigated the effect of fetal
calf serum (FCS) on the regulation of TGF-beta after
transfection with siLDH-A to exclude a starving effect (B). As in
the assay using 0% FCS (Figure 4F), a slight induction of TGF-
beta2 protein after treatment with lactic acid and NaLactate
could be detected under culturing conditions with 5% FCS.
(TIFF)
Figure S3.  Brain tumor initiating cells. Results were
repeated in brain tumor initiating cells. LDH-A knockdown with
0.1 µM siLDH-A leads to a decrease of TGF-beta2 mRNA in
RAV20 and RAV21 brain tumor initiating cells (A, p < 0.05*).
Treatment of RAV-20 with lactic acid (pH 6.4) and sodium
lactate (pH 7.4), but not HCl, leads to an induction of TGF-
beta2 mRNA in qRT-PCR 24 hours after treatment (B, lactate p
< 0.05*; lactic acid p < 0.01**). Down-regulation of LDH-A and
THBS-1 by siRNA leads to significantly reduced mRNA levels
(C, siLDH-A p < 0.01**; siTHBS-1 p < 0.01**). Finally,
treatment of RAV20 with HCl (p < 0.01**), sodium lactate (pH
7.4; p < 0.001***) and lactic acid (pH 6.4; p < 0.001***)
significantly increases THBS-1 mRNA level in qRT-PCR (D).
(TIFF)
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